Literature DB >> 24733468

Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method.

S P van Rijn1, A M A Wessels1, B Greijdanus1, D J Touw1, J W C Alffenaar2.   

Abstract

Ertapenem, a carbapenem, relies on time-dependent killing. Therapeutic drug monitoring (TDM) should be considered, when ertapenem is used in specific populations, to achieve optimal bactericidal activity and optimize drug-dosing regimens. No validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been reported using deuterated ertapenem as the internal standard. A new simple and robust LC-MS/MS method using a quadrupole mass spectrometer was developed for analysis of ertapenem in human plasma, using deuterated ertapenem as the internal standard. The calibration curve was linear over a range of 0.1 (lower limit of quantification [LLOQ]) to 125 mg/liter. The calculated accuracy ranged from -2.4% to 10.3%. Within-run coefficients of variation (CV) ranged from 2.7% to 11.8%, and between-run CV ranged from 0% to 8.4%. Freeze-thaw stability had a bias of -3.3% and 0.1%. Storage of QC samples for 96 h at 4°C had a bias of -4.3 to 5.6%, storage at room temperature for 24 h had a bias of -10.7% to -14.8%, and storage in the autosampler had a bias between -2.9% and -10.0%. A simple LC-MS/MS method to quantify ertapenem in human plasma using deuterated ertapenem as the internal standard has been validated. This method can be used in pharmacokinetic studies and in clinical studies by performing TDM.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24733468      PMCID: PMC4068466          DOI: 10.1128/AAC.00025-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  José A Caminero; Giovanni Sotgiu; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Lancet Infect Dis       Date:  2010-09       Impact factor: 25.071

2.  Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.

Authors:  A J Brink; G A Richards; V Schillack; S Kiem; J Schentag
Journal:  Int J Antimicrob Agents       Date:  2008-12-16       Impact factor: 5.283

3.  Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations.

Authors:  Olaf Burkhardt; Vipul Kumar; Stephan Schmidt; Jan T Kielstein; Tobias Welte; Hartmut Derendorf
Journal:  Int J Antimicrob Agents       Date:  2009-11-06       Impact factor: 5.283

4.  Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Authors:  M Chen; A N Nafziger; G L Drusano; L Ma; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Pharmacokinetics of ertapenem in healthy young volunteers.

Authors:  A K Majumdar; D G Musson; K L Birk; C J Kitchen; S Holland; J McCrea; G Mistry; M Hesney; L Xi; S X Li; R Haesen; R A Blum; R L Lins; H Greenberg; S Waldman; P Deutsch; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis.

Authors:  Goutam C Mistry; Anup K Majumdar; Suzanne Swan; Domenic Sica; Alison Fisher; Yang Xu; Michael Hesney; Liwen Xi; John A Wagner; Paul J Deutsch
Journal:  J Clin Pharmacol       Date:  2006-10       Impact factor: 3.126

7.  The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin.

Authors:  Radhika Gupta; Marie Lavollay; Jean-Luc Mainardi; Michel Arthur; William R Bishai; Gyanu Lamichhane
Journal:  Nat Med       Date:  2010-03-21       Impact factor: 53.440

Review 8.  Pharmacokinetic and pharmacodynamic properties of meropenem.

Authors:  David P Nicolau
Journal:  Clin Infect Dis       Date:  2008-09-15       Impact factor: 9.079

9.  Pharmacokinetics of ertapenem in burns patients.

Authors:  E Dailly; J F Arnould; F Fraissinet; E Naux; M A Letard de la Bouralière; R Bouquié; G Deslandes; P Jolliet; R Le Floch
Journal:  Int J Antimicrob Agents       Date:  2013-04-08       Impact factor: 5.283

10.  Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.

Authors:  Jean-Emmanuel Hugonnet; Lee W Tremblay; Helena I Boshoff; Clifton E Barry; John S Blanchard
Journal:  Science       Date:  2009-02-27       Impact factor: 47.728

View more
  4 in total

1.  Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis.

Authors:  Shashikant Srivastava; Sander P van Rijn; A Mireille A Wessels; Jan-Willem C Alffenaar; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

2.  Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Authors:  M A Zuur; S Ghimire; M S Bolhuis; A M A Wessels; R van Altena; W C M de Lange; J G W Kosterink; D J Touw; T S van der Werf; O W Akkerman; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.

Authors:  Sander P van Rijn; Shashikant Srivastava; Mireille A Wessels; Dick van Soolingen; Jan-Willem C Alffenaar; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

Authors:  S P van Rijn; M A Zuur; R van Altena; O W Akkerman; J H Proost; W C M de Lange; H A M Kerstjens; D J Touw; T S van der Werf; J G W Kosterink; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.